Hologic — Cytyc — Merger or Acquisition (May 2007)
27 slides from Hologic's merger presentation, May 21, 2007
Slide 1: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare Continuing a legacy of leading technology, innovation and rapid growth May 21, 2007
Slide 2: Disclaimer Regarding Forward-Looking Statements
Disclaimer Regarding Forward-Looking Statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the timing of the completion of the tra
Slide 3: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-party reimbursement; realization of potential future savings from new productivity init
Slide 4: Important Information for Investors and Stockholders
Important Information for Investors and Stockholders Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OT
Slide 5: Participants in the Solicitation
Participants in the Solicitation Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic’s directors and executive officers and a description of their
Slide 6: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and “EBITDA”. Adjusted EPS excludes the write-off and amortization of acquisition-related intang
Slide 7: Presenters: Patrick Sullivan, Jack Cumming, Glenn Muir
Patrick Sullivan Chairman, President and CEO of Cytyc Jack Cumming Chairman and CEO of Hologic Glenn Muir Chief Financial Officer of Hologic
Slide 8: Patrick Sullivan, Chairman, President and CEO, Cytyc
Patrick Sullivan Chairman, President and CEO, Cytyc
Slide 9: Strategic Rationale Combined Strengths
Strategic Rationale Combined Strengths Expanded Product Portfolio Comprehensive Sales Coverage Ability to Leverage OB/GYN Channel Significant Cross-Selling Synergies Enhanced International Presence Creating a Global Leader in Women’s Healthcare Market Share Leader in Major Product Lines Proven Manag
Slide 10: Comprehensive Women's Healthcare Platform
MultiCare Stereotactic Biopsy Discovery Osteoporosis Screening Selenia Breast Cancer Screening MammoSite Radiation Therapy ThinPrep Pap Test & Imaging System Cervical Cancer Screening NovaSure Endometrial Ablation Adiana Contraception FullTerm - Adeza Preterm Labor Best-in-Class Solutions in Women’s
Slide 11: Jack Cumming, Chairman and CEO, Hologic
Jack Cumming Chairman and CEO, Hologic
Slide 12: Powerful Strategic Logic
Comprehensive Channel Coverage Proven Track Record Enhanced International Presence Broad Product Portfolio Creates Industry Leader Powerful Strategic Logic Largest sales and service organization focused on women’s healthcare in U.S. Leverage commercial strengths across multiple physician specialties
Slide 13: Powerful Financial Logic
Significant Synergies Enhanced Diversification Strong Cash Flow Solid Financial Profile Accretive Within the First Full Year After Close Powerful Financial Logic $75M+ projected cross-selling opportunities to drive top-line growth Projected cost savings of approximately $25M to $30M within two years
Slide 14: Solutions for Major Women's Healthcare Issues
Endometriosis Permanent Contraception Preterm Labor Osteoporosis Menorrhagia Cervical Cancer Breast Cancer Solutions for Major Women’s Healthcare Issues Helica Unpenetrated 1 in 3 Gestiva International ThinPrep Imaging System International Tomosynthesis Suros Celero Additional Opportunities Adiana F
Slide 15: Leveraging the OB/GYN Channel
everaging the OB/GYN Channel Best Technology Scere, Minimally Invasive Channel Access to ‘Mdera, Diseavers” Most Specific Gatekeeper “= Sures, MultiCare, Selenia, Discovery » 230 OBIG: Screening ‘ Diagnostic Test <j Improved. {pe Outcomes Treatment Specialist Therapeutic Channel Access to Treatment
Slide 16: In-Depth Channel Coverage
58 Breast Surgery & Radiation Oncology 77 Radiology & Imaging Center 110 Gynecology Surgery Over 425 U.S. Sales Representatives OB/Gyn & Primary Care Physicians Clinical Lab Multiple call points to women’s healthcare providers Access to – 30,000 OB/Gyn’s – 40,000 Radiologists – 10,000 Hospitals & Im
Slide 17: Enhanced International Presence
Enhanced International Presence Commercial presence in over 125 countries around the world UK Spain France Italy Germany Switzerland MA Australia Hong Kong Costa Rica China Mexico Brazil South Africa Japan Canada Belgium Legend Company presence Key distributors CA IN DE CT
Slide 18: Long-Term Strategic Goals
Drive market growth through a combination of advanced technology and comprehensive sales channel coverage #1 market position in major areas of women’s healthcare Continue 20%+ revenue and earnings growth Develop additional best-in-class products that provide earlier and better detection, improved di
Slide 19: Glenn Muir, Chief Financial Officer, Hologic
Glenn Muir Chief Financial Officer, Hologic
Slide 20: Transaction Overview
Permanent financing anticipated to be combination of pre-payable term loan and equity-linked securities Financing: Hologic, Inc. (NASDAQ: HOLX), continue Cytyc name Name of NewCo: Third Quarter of CY2007 Timing to Close: Shareholders of both companies, customary closing conditions and anti-trust cle
Slide 21: Financial Rationale
Multiple platforms to enhance top and bottom line growth Increased scale through diversification of revenue and strong margin profile Enhanced cash flow; LQA EBITDA of ~$436M Revenue and cost synergy opportunities Estimated more than $0.10 accretive to adjusted EPS within the first full year after c
Slide 22: Diversified and Balanced Revenue Mix
NovaSure 30% Pap 56% Digital Mammography 68% Gynecology Interventional 16% Gynecology Diagnostics 33% Breast Health 40% Osteoporosis & Other 11% Other 1% MammoSite 5% Adeza 8% Other 12% Breast Biopsy 9% Osteoporosis 11% Diversified and Balanced Revenue Mix Hologic Combined Company LQA Revenue = $724
Slide 23: Combined Financial Strength
Combined Financial Strength 46% Gross Margin $161M EBITDA $724M Revenue LQA Hologic 75% Gross Margin $275M EBITDA $720M Revenue LQA Cytyc 60% Gross Margin $436M EBITDA $1.44B Revenue LQA Combined Company
Slide 24: Significant Synergy Opportunity
$25-$30M projected cost savings within two years Align assets to maximize efficiencies Leverage combined purchasing power Consolidate administrative activities Greater than $75M revenue projected opportunities within three years Cross-selling Enhanced geographic reach Penetration of new and existing
Slide 25: FY2008 Guidance and Long Term Outlook
FY2008 Guidance and Long Term Outlook 2008 Guidance Revenue: In excess of $1.70B Adjusted EPS : $2.35-2.40 / share Gross margin: 65% Long-Term Outlook Revenue Growth: 20% Adjusted EPS Growth: 20%+ Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and rela
Slide 26: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare Comprehensive Women’s Healthcare Product Portfolio – Complementary best-in-class technologies Expanded Commercial Capabilities – Expansive U.S. sales channel coverage – Enhanced presence in key international markets – Platform for entry into new markets
Slide 27: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare